Cantor Fitzgerald Maintains Overweight on Soleno Therapeutics, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska maintains an Overweight rating on Soleno Therapeutics (NASDAQ:SLNO) and raises the price target from $19 to $35.
September 26, 2023 | 2:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald maintains an Overweight rating on Soleno Therapeutics and raises the price target from $19 to $35.
The news is directly related to Soleno Therapeutics. The Overweight rating maintained by Cantor Fitzgerald and the increase in price target from $19 to $35 indicates a positive outlook for the company. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100